These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 15870865)
1. Cox-2 and Her2/neu co-expression in invasive bladder cancer. Eltze E; Wülfing C; Von Struensee D; Piechota H; Buerger H; Hertle L Int J Oncol; 2005 Jun; 26(6):1525-31. PubMed ID: 15870865 [TBL] [Abstract][Full Text] [Related]
2. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy]. Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605 [TBL] [Abstract][Full Text] [Related]
3. [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications]. Wülfing C; Eltze E; Von Struensee D; Wülfing P; Bode ME; Bettendorf O; Piechota H; Hertle L Aktuelle Urol; 2004 Aug; 35(4):331-8. PubMed ID: 15459875 [TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. Shariat SF; Kim JH; Ayala GE; Kho K; Wheeler TM; Lerner SP J Urol; 2003 Mar; 169(3):938-42. PubMed ID: 12576817 [TBL] [Abstract][Full Text] [Related]
5. Overexpression of laminin-5 gamma2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: association with expression of cyclooxygenase 2, epidermal growth factor receptor [corrected] and human epidermal growth factor receptor [corrected] 2. Kiyoshima K; Oda Y; Kinukawa N; Naito S; Tsuneyoshi M Hum Pathol; 2005 May; 36(5):522-30. PubMed ID: 15948119 [TBL] [Abstract][Full Text] [Related]
6. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684 [TBL] [Abstract][Full Text] [Related]
7. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482 [TBL] [Abstract][Full Text] [Related]
8. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17. Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884 [TBL] [Abstract][Full Text] [Related]
9. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. Shariat SF; Matsumoto K; Kim J; Ayala GE; Zhou JH; Jian W; Benedict WF; Lerner S J Urol; 2003 Sep; 170(3):985-9. PubMed ID: 12913755 [TBL] [Abstract][Full Text] [Related]
10. HER2/neu expression in bladder cancer: relationship to cell cycle kinetics. Eissa S; Ali HS; Al Tonsi AH; Zaglol A; El Ahmady O Clin Biochem; 2005 Feb; 38(2):142-8. PubMed ID: 15642276 [TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Half E; Tang XM; Gwyn K; Sahin A; Wathen K; Sinicrope FA Cancer Res; 2002 Mar; 62(6):1676-81. PubMed ID: 11912139 [TBL] [Abstract][Full Text] [Related]
12. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506 [TBL] [Abstract][Full Text] [Related]
13. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer. Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129 [TBL] [Abstract][Full Text] [Related]
14. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies? Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595 [TBL] [Abstract][Full Text] [Related]
15. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization. Matsubara H; Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Honda N Oncol Rep; 2008 Jan; 19(1):57-63. PubMed ID: 18097576 [TBL] [Abstract][Full Text] [Related]
16. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Krüger S; Weitsch G; Büttner H; Matthiensen A; Böhmer T; Marquardt T; Sayk F; Feller AC; Böhle A Int J Oncol; 2002 Nov; 21(5):981-7. PubMed ID: 12370744 [TBL] [Abstract][Full Text] [Related]
17. Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract. Miyata Y; Kanda S; Nomata K; Eguchi J; Kanetake H J Urol; 2005 Jan; 173(1):56-60. PubMed ID: 15592025 [TBL] [Abstract][Full Text] [Related]
18. Novel approach of human epidermal growth factor receptor 2 detection in noninvasive and invasive transitional cell carcinoma of the bladder. Hauser-Kronberger C; Peham K; Grall J; Rausch W; Hutarew G; Dietze O J Urol; 2006 Mar; 175(3 Pt 1):875-80; discussion 880. PubMed ID: 16469569 [TBL] [Abstract][Full Text] [Related]
19. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression. Chen PC; Yu HJ; Chang YH; Pan CC J Clin Pathol; 2013 Feb; 66(2):113-9. PubMed ID: 23087329 [TBL] [Abstract][Full Text] [Related]